Quantcast

IMRISneuro to be installed at Yale-New Haven Hospital

January 12, 2009

WINNIPEG, Jan. 12, 2009 /PRNewswire-FirstCall/ – IMRIS Inc. (TSX: IM) (“IMRIS” or the “Company”) today announced the sale of their flagship product, IMRISneuro, to Yale-New Haven Hospital in New Haven, Connecticut, one of the leading neuroscience centers in the U.S.

The only one of its kind in the world, IMRISneuro incorporates a movable high-field MRI with a state-of-the-art integration platform, IMRISmatrix, allowing the surgical team to scan, view and share critical patient information during a procedure. At Yale-New Haven Hospital, the IMRISneuro system will move between two operating theatres and a diagnostic center, providing leading edge, multi-functional capabilities to the hospital’s neuroscience team.

“We are confident that in the hands of the surgeons at Yale-New Haven Hospital, IMRISneuro can make a major contribution towards providing patients with the highest standard of treatment and care,” said David Graves, President and CEO of IMRIS.

The purchase is contingent upon the receipt of a Certificate of Public Need from the State of Connecticut.

About IMRIS

IMRIS (TSX: IM) is a global leader in providing fully integrated, advanced surgical imaging solutions. The company’s flagship product, IMRISneuro, utilizes patented technology that allows a high field MRI scanner to be moved in to the operating room on demand, providing imaging during the surgical procedure without compromising patient safety. This unique and innovative system has been validated by leading neurosurgeons for use in world-class neuroscience centers.

For more information, visit www.imris.com.

SOURCE IMRIS Inc.


Source: newswire



comments powered by Disqus